CLSI Standards Documents for Public Review
Comment on New and Revised Standards Drafts
Help shape the standards that affect your day-to-day work. To preserve the integrity of standards developed through the CLSI consensus process, we seek input from the public on our in-process draft documents before they are approved for publication. Opening the dialogue to CLSI members and nonmembers alike, we encourage your involvement in shaping our documents to ensure all interested parties are given a voice.
Requests for documents should be submitted via e-mail to email@example.com or by fax to +1.610.688.0700. Comments related to CLSI draft documents shall be made in writing using the comment table form and shall be submitted no later than the comment deadline indicated below.
CLSI Standards Documents for Public Review and Comment
M24 (Proposed Draft)—Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. This standard provides protocols and related quality control parameters for antimicrobial susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. This draft document is available to the public for review and comment for 60 days (10 April to 8 June 2018).
M44 (Proposed Draft)—Method for Antifungal Disk Diffusion Susceptibility Testing of Yeast. This guideline provides an established methodology for disk diffusion testing of Candida spp., along with recommendations for results interpretation and quality control testing. This draft document is available to the public for review and comment for 60 days (10 April to 8 June 2018).
C34 (Proposed Draft)—Sweat Testing: Specimen Collection and Quantitative Chloride Analysis. This guideline describes methods for all aspects of sweat testing, including collection and analysis, result evaluation and reporting, and quality control. This draft document is available to the public for review and comment for 60 days (15 May to 13 July 2018).
NBS05 (Proposed Draft)—Newborn Screening for Cystic Fibrosis. This guideline describes newborn screening laboratory tests for detecting analytes and genetic markers associated with cystic fibrosis (CF). It includes both the primary screening tests and reflex tests performed on newborn dried blood spot specimens, as well as the screening strategies for identifying babies at increased risk for developing CF. This draft document is available to the public for review and comment for 60 days (15 May to 13 July 2018).
The review and comment period provides an opportunity for the public to offer input on CLSI draft consensus documents. At the end of the 60-day review and comment period, the committee that developed the document is required to review and provide responses to all comments received and revise the draft document as appropriate.
Please note CLSI draft documents are available only for the purposes of review and comment and are not to be reproduced or circulated for any other reason. Draft documents have not completed the consensus review process and therefore shall not be used for any clinical purposes or to satisfy regulatory or accreditation requirements. They should not be considered either final or published and may not be quoted or referenced.